Does Acyclovir Maintenance Therapy Cause Drug Resistance?
Yes, long-term acyclovir maintenance therapy can lead to drug resistance, particularly in immunocompromised patients with frequent herpes simplex virus (HSV) or varicella-zoster virus (VZV) recurrences. Resistance develops when viral thymidine kinase (TK) or DNA polymerase mutations reduce drug efficacy, occurring in 5-10% of HSV cases after prolonged suppression in AIDS patients or transplant recipients.[1][2]
How Common Is Resistance in Maintenance Therapy?
Resistance rates stay low in immunocompetent individuals (under 1%) even with years of daily acyclovir for genital herpes suppression.[3] In high-risk groups like HIV patients or stem cell transplant recipients, rates climb to 4-7% for HSV and up to 30% for acyclovir-resistant VZV after 1-2 years of continuous use.[1][4] Factors like poor adherence, high viral load, or prior episodic therapy accelerate emergence.
What Mechanisms Drive Acyclovir Resistance?
Acyclovir requires viral TK to phosphorylate it into its active form, which then inhibits DNA polymerase. Common mutations:
- TK-negative/altered (95% of HSV cases): Virus loses TK activity, blocking activation.
- TK-partial or DNA polymerase mutations (5%): Reduced binding affinity.[2][5]
These confer cross-resistance to valacyclovir and famciclovir but not always foscarnet or cidofovir.
Who Is Most at Risk?
Immunocompromised patients face highest risk:
| Patient Group | Resistance Rate (HSV/VZV) | Typical Timeline |
|---------------|---------------------------|------------------|
| HIV/AIDS on suppressive therapy | 5-10% HSV | 6-12 months [1] |
| Bone marrow transplant | 20-30% VZV | 3-6 months [4] |
| Solid organ transplant | 4-7% HSV | 1-2 years [6] |
| Immunocompetent | <0.5% | Rare, even long-term [3] |
How Do Doctors Detect and Manage Resistance?
Suspect resistance if lesions persist despite therapeutic doses (e.g., >800 mg/day acyclovir). Confirm via plaque reduction assay or genotypic testing for TK/polymerase mutations.[5] Switch to IV foscarnet (for severe cases) or imiquimod topicals; cidofovir for VZV. Reduce suppression duration or use intermittent therapy to mitigate risk.[2][7]
Can Resistance Reverse or Be Prevented?
Resistance persists in the viral population but may wane if therapy stops and wild-type virus dominates. Prevention includes baseline susceptibility testing in high-risk patients, dosing optimization, and reserving maintenance for those with >6 recurrences/year.[3][6] No vaccines yet target resistant strains.
Sources
[1] CDC Guidelines on HSV Management
[2] Journal of Infectious Diseases: Acyclovir Resistance Review (2010)
[3] NEJM: Long-term Acyclovir Suppression (1998)
[4] Clinical Infectious Diseases: VZV Resistance in Transplant Patients (2002)
[5] Antiviral Research: Mechanisms of Resistance (2015)
[6] American Journal of Transplantation: HSV in Solid Organ Transplant (2013)
[7] IDSA Guidelines: Antiviral Therapy (2018)